Related Experiment Videos

Rapid deterioration of diabetic retinopathy during treatment with continuous subcutaneous insulin infusion

Diabetes Care
|May 1, 1984
PubMed

Insights

Continuous subcutaneous insulin infusion (CSII) did not reverse diabetic retinopathy in most patients. However, some with advanced disease experienced rapid worsening, indicating potential risks for specific diabetic populations.

Area of Science:

  • Ophthalmology
  • Endocrinology
  • Diabetology

Background:

  • Investigated the impact of continuous subcutaneous insulin infusion (CSII) on diabetic retinopathy progression.
  • Study included 19 patients with insulin-dependent diabetes mellitus (IDDM), all diagnosed before age 30.
  • Patients presented with varying stages of retinopathy, from none to preproliferative.

Observation:

  • Metabolic control significantly improved with CSII.
  • Despite improved control, no reversal of existing retinopathy was observed.
  • Some patients showed stable or slightly worsened retinopathy, while four experienced rapid progression to proliferative diabetic retinopathy.

Findings:

  • Four patients with pre-existing moderate-to-severe retinopathy rapidly progressed to florid proliferative diabetic retinopathy within 3-6 months of CSII initiation.
  • This rapid progression was associated with long-standing, poorly controlled diabetes, neuropathy, and nephropathy.
  • Two of these four patients also experienced significant declines in glomerular filtration rate (GFR).

Implications:

  • CSII may accelerate retinopathy progression in specific diabetic patients with advanced disease and complications.
  • Careful patient selection and monitoring are crucial when initiating CSII in individuals with established diabetic retinopathy and related complications.
  • Further research is needed to understand the mechanisms behind CSII-induced retinopathy acceleration in high-risk individuals.

Related Concept Videos